Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(1998): Knowles S+, JAmAcadDermatol38, 201 (passim)
(1995): Avila JR+, Ann Pharmacother 29, 317
(1993): Kitamura K+, JDermatol20, 279 (psoriasiform) (31%)
(1993): Sanders CJ+, Lancet 341, 967
(1993): Sousa-Basto A+, Contact Dermatitis 29, 44
(1992): Wittal RA+, Australas J Dermatol 33, 11
(1989): Berbis P+, Dermatologica 179, 90
(1989): Brown FH+, Ann Dent 48, 39
(1989): Stern R+, Arch Intern Med 149, 829
Exanthems
(2000): Heymann WR, Cutis 66, 129
(1998): Knowles S+, JAmAcadDermatol38, 201 (passim)
(1994): Baker BA+, Ann Pharmacother 28, 118
(1993): Kitamura K+, JDermatol20, 279 (psoriasiform) (31%)
(1993): Sousa-Basto A+, Contact Dermatitis 29, 44
(1992): Romano A+, Ann Allergy 69, 31
(1992): Wittal RA+, Australas J Dermatol 33, 11 (erythroderma)
(1990): Wirebaugh SR+, Drug Intell Clin Pharm 24, 1046
(1989): Jones SK+, Clin Exp Dermatol 14, 457
(1989): Stern R+, Arch Intern Med 149, 829
(1988): Hammentgen R+, Dtsch Med Wochenschr (German)
113, 1283
(1988): Lambert DG+, Br J Dermatol 118, 308 (passim)
(1988): Wakeel RA+, BMJ 296, 1071 (passim)
(1986): Gibson RS+, NEnglJMed315, 423 (0.7%)
(1985): Chaffman M+, Drugs 29, 387 (1.3%)
(1985): Scolnick B+, AnnInternMed102, 558
Exfoliative dermatitis (